Navigation Links
Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
Date:10/4/2010

SAN DIEGO, Oct. 4 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the 28th Annual Scientific Meeting of The Obesity Society. This meeting will be held at the San Diego Convention Center, October 8-12, 2010.Sunday, October 10:  Embargo Lifts October 10 at 12:30 p.m. PTPoster Presentation
Abstract: 478-P
Presenter: Louis Aronne, M.D., New York Weill Cornell-Columbia Presbyterian Hospital, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Markers of Cardiometabolic Risk: A Pooled Analysis of Two Phase 3, 56-Week, Double-Blind, Placebo-Controlled Studies"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 480-P
Presenter: Ken Fujioka, M.D., Scripps Clinic, La Jolla, CA
Title: "Naltrexone SR/Bupropion SR Combination Therapy Improves Control of Eating and Reduces Food Cravings in Overweight/Obese Subjects"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 482-P
Presenter: F. Xavier Pi-Sunyer, M.D., St. Luke's-Roosevelt Hospital and Columbia University, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Had No Effect on Depression or Suicidal Ideation: A Pooled Analysis From the Contrave Obesity Research Program"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 479-P
Presenter: Raymond A. Plodkowski, M.D., University of Nevada School of Medicine, Reno, NV
Title: "COR I: Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Weight-Related Quality of Life in a Phase 3, 56-Week, Double-Blind, Placebo-Controlled Study"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 481-P
Presenter: Susan L. McElroy, M.D., Lindner Center of Hope, Mason, OH
Title: "Reduced Depressive Symptoms and Weight loss in Depressed Overweight/Obese
Subjects Completing 24 Weeks of Open Label Therapy with Naltrexone SR/Bupropion SR"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H
Poster Presentation
Abstract: 499-P
Presenter: Domenica Rubino, M.D., Washington Center for Weight Management & Research, Arlington, VA
Title: "Naltrexone SR/Bupropion SR Combination (NB) Therapy Shifts Subjects From the Obese to the Non-obese Body Mass Index (BMI) Classes—From the COR-II Phase 3, Double-blind, Placebo-controlled, 56-week Study"
Time: 12:30 – 1:30 p.m. PT
Location: Hall HAbout Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
2. Pepscan Therapeutics Announces Establishment of Scientific Advisory Board
3. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
4. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
5. Talecris Biotherapeutics GmbH Awards Winners of the 7th Annual European ALTA Research Fellowship at 2010 ERS Meeting
6. Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders
7. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
8. Reportlinker Adds Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
9. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
10. Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange
11. Reportlinker Adds Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/24/2016)... Israel , May 24, 2016   MedyMatch Technology ... physicians with artificial intelligence, real-time decision support tools in the ... present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed ... Israel,s 15th National Life Sciences and ... at the David Intercontinental Hotel in Tel Aviv, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, ... new Media Cybernetics corporate branding reflects a results-driven revitalization for a company with ... The re-branding components include a crisp, refreshed logo and a new web presence. ...
Breaking Biology Technology:
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):